Open AccessInvestigating the cytotoxic and apoptotic effects of sunitinib upon K-562 chronic myelogenous leukemia cell line and assessment of gene profiling
Author(s) -
Melda Cömert Özkan,
Burçin Tezcanlı Kaymaz,
Ajda Güneş,
Birsen Can,
Nur Soyer,
Asu Fergün Yılmaz,
Fılız Vural,
Fahri Şahin,
Güray Saydam
Publication year - 2020
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_983_17
Subject(s) - sunitinib , cancer research , cytotoxic t cell , apoptosis , chronic myelogenous leukemia , myeloid leukemia , cell growth , biology , tyrosine kinase , pharmacology , leukemia , microbiology and biotechnology , signal transduction , immunology , cancer , in vitro , biochemistry , genetics
Tyrosine kinase inhibitors (TKIs) which efficiently inhibit BCR-ABL are highly effective for clinical treatment of chronic myeloid leukemia (CML), but development of resistance to TKIs is a big challenge to treatment. Sunitinib is a multitargeted TKI targeting vascular endothelial growth factor receptor and is defined a safe and effective candidate target, but its effect on other signaling pathways is unknown. To investigate the cytotoxic and apoptotic effect of sunitinib in CML cell model K-562 on JAK-STAT signaling pathway components, suppressor genes and oncogenes, hematopoiesis-related genes, cell cycle and VEGF pathway components, and mRNA level expression changes was aimed.